



Published in final edited form as:

Cancer Cell. 2011 January 18; 19(1): 5–6. doi:10.1016/j.ccr.2011.01.006.

Keratin 15-Positive Stem Cells Give Rise To Basal Cell Carcinomas In Irradiated Ptch+/- Mice

John T. Seykora, MD, PhD and George Cotsarelis, MD

Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA, 19104

Abstract

The cell of origin for basal cell carcinoma (BCC) remains controversial. In this issue of *Cell Stem Cell*, Wang et al. provide strong evidence that BCC arise from hair follicle stem cells.

Over twenty years ago we localized a population of presumptive stem cells to the hair follicle bulge (Cotsarelis et al., 1990). Both mouse and human bulge cells possess a quiescent phenotype that contrasts with the much higher proliferative rate of the cells within other compartments of the cutaneous epithelium (Lyle et al., 1998). We proposed that the bulge ‘stem’ cells were the origin for skin cancers primarily because their long-lived nature would permit accumulation of multiple genetic hits required for tumor formation. At that time, we asked, “What are the relative contributions of the follicle and IFE in giving rise to various human skin carcinomas?” With respect to cutaneous basal cell carcinoma (BCC), the most common type of cancer, this question awaited the development of molecular tools for targeting bulge cells as well as the development of mouse models of BCC.

Genetic lineage analysis of bulge cells became possible with the discovery of the Keratin 15 (K15) promoter that preferentially targets stem and progenitor cells in the bulge and adjacent secondary germ (Morris et al., 2004). The inducible K15-CrePR1;R26R mouse was used to demonstrate that bulge cells generated all epithelial lineages during hair follicle cycling when the lower follicle regenerates, and that these cells contributed keratinocytes to healing wounds (Ito et al., 2005; Morris et al., 2004). The K15 promoter could then be used to target bulge cells in mouse models of skin cancer to determine if hair follicle stem cells contributed to cutaneous carcinogenesis.

Two recent studies took this approach and came to different conclusions. Blanpain and coworkers published that basal cell carcinomas in a *Smoothed 2* transgenic overexpression model did not arise from hair follicle bulge cells (Youssef et al., 2010). In contrast, Epstein and colleagues report that irradiated Ptch+/- mice develop BCCs almost exclusively from hair follicle bulge cells (Wang, 2011). Understanding this discrepancy is critical for the field and has implications on developing treatments for human BCCs.

BCCs in humans occur spontaneously or as part of hereditary syndromes such as basal cell nevus syndrome (BCNS). BCNS patients generally carry one mutated *Ptch* gene, which encodes a receptor for hedgehog proteins, and develop BCCs through loss of heterozygosity of the remaining *Ptch* allele. The large majority of spontaneous basal cell carcinomas also possess loss-of-function mutations in the *patched* gene that leads to activation of the hedgehog pathway. Basal cell carcinomas without *Ptch* mutations may possess activating mutations in other genes in the hedgehog pathway such as the signal transducer *Smoothed* (*Smo*). Thus, activating mutations in the hedgehog pathway are a hallmark of human basal cell carcinomas. Since *Ptch* is a hedgehog target gene, basal cell carcinomas overexpress *Ptch* mRNA and this can be used as a marker for basal cell carcinoma.

The hedgehog pathway is critical for development of hair follicles. Interestingly, in the normal ? human and murine adult epidermis, little to no expression of *Ptch* or its ligand, *Shh*, is detected. These genes are expressed primarily in the hair follicle and only at specific times during hair follicle cycling in the adult. This raises the possibility that loss of *Ptch* in the interfollicular epidermis (IFE) may not immediately impact epidermal keratinocyte behavior. Consistent with this, transgenic mice that overexpress *Shh* in skin develop tumor-like changes primarily in their hair follicle epithelium rather than in their IFE (Oro et al., 1997).

Human BCCs generally possess two mutated alleles, often with UV signatures, of *Ptch*. Loss of *Ptch* function results in overexpression of hedgehog target genes since *Ptch* normally represses these. Epstein and colleagues developed a *Ptch*^{+/-} mouse that forms BCCs following UV or ionizing radiation. This mouse phenocopies the BCNS patient in that both develop medulloblastomas and rhabdomyosarcomas as well as BCCs. Thus, this mouse model seems ideal for studying the development of BCC and for answering the ontologic question of whether BCCs arise from hair follicle bulge cells or from other epithelial cells. Wang et al crossed the *Ptch*^{+/-} mouse with the *K15-CrePR;R26R* mouse, induced labeling of the bulge cells, irradiated the mice, then evaluated the resulting tumors for expression of *LacZ* that would indicate a bulge stem cell contribution? (Wang, 2011). Taking into account the efficiency of the inducible system, they showed that the great majority of BCCs arose from *K15*-positive bulge cells.

The cell of origin of human BCC has been debated for decades; however, dermatopathologists generally hold the view that “superficial (multicentric)” BCCs arise from the IFE while some portion of nodular BCCs arise from the follicle. Previous studies on human BCCs showed that most of these tumors express keratins associated with follicular keratinocytes. Interestingly, when immunostained for *K15* protein, the bulge cell marker, approximately one third of nodular BCCs stained positively, while none of the superficial BCCs stained; thus, providing evidence that a substantial portion of human nodular BCCs arise from the hair follicle bulge (Jih et al., 1999).

Other types of mouse models for basal cell carcinoma depend on overexpression of genes in the hedgehog pathway, such as *Gli* and *Smo*. For example, targeting of *Gli* expression to the follicle and IFE results in the formation of basal cell tumors that clinically resemble human basal cell carcinomas in that they have a translucent appearance and the presence of small

vessels known as telangiectasias (Grachtchouk et al., 2000; Nilsson et al., 2000). These tumors are dependent on continuous Gli expression and regress if the transgene is turned off. Results of early clinical trials suggest that human BCCs are similarly “addicted” to hedgehog signaling and may be amenable to targeted therapy.

In 2003, Dlugosz and colleagues published that constitutive overexpression of activated Smo in the epidermis resulted in basaloid hamartomas (Grachtchouk et al., 2003). These investigators were careful to distinguish between basaloid hamartomas and BCC because basaloid hamartomas, both in humans and in mice, have limited growth potential and rarely develop into BCC. In a more recent study, Blanpain and colleagues also overexpressed activated Smo in the epidermis, but using an inducible system, and described the formation of “basal cell carcinomas.” (Youssef et al., 2010) One common problem with both the Blanpain and the Wang papers rests on whether the tumors that developed are truly BCCs or whether they are basaloid hamartomas. Input from a dermatopathologist is essential for making the distinction. It is entirely possible that many if not most of the tumors would be classified as basaloid hamartomas. Nonetheless, these findings do suggest that non-bulge cells have a lower threshold than bulge cells for tumor development in response to K14-induced oncogenic Smo.

Wang et al suggest that loss of p53 triggers Smo expression in epidermis of Ptch+/- mice. Since Smo is an obligatory activator of Hh signaling, the resultant epidermal BCCs in irradiated p53-deficient Ptch+/- mice suggests that loss of p53 may be a primary event in BCC formation, operating through the novel mechanism of Smo upregulation. This important concept deserves testing in both human epidermis with known p53 mutations and in mouse models. The findings could impact on future targeting of incipient BCC with chemotherapeutic agents.

References

- Cotsarelis G, Sun TT, Lavker RM. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. *Cell*. 1990; 61:1329–1337. [PubMed: 2364430]
- Grachtchouk M, Mo R, Yu S, Zhang X, Sasaki H, Hui CC, Dlugosz AA. Basal cell carcinomas in mice overexpressing Gli2 in skin. *Nat Genet*. 2000; 24:216–217. [PubMed: 10700170]
- Grachtchouk V, Grachtchouk M, Lowe L, Johnson T, Wei L, Wang A, de Sauvage F, Dlugosz AA. The magnitude of hedgehog signaling activity defines skin tumor phenotype. *EMBO J*. 2003; 22:2741–2751. [PubMed: 12773389]
- Ito M, Liu Y, Yang Z, Nguyen J, Liang F, Morris RJ, Cotsarelis G. Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. *Nat Med*. 2005; 11:1351–1354. [PubMed: 16288281]
- Jih D, Lyle S, Elenitsas R, Elder D, Cotsarelis G. Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells. *J Cutan Pathol*. 1999; 26:113–118. [PubMed: 10235375]
- Lyle S, Christofidou-Solomidou M, Liu Y, Elder DE, Albelda S, Cotsarelis G. The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. *J Cell Sci*. 1998; 111:3179–3188. [PubMed: 9763512]
- Morris RJ, Liu Y, Marles L, Yang Z, Trempus C, Li S, Lin JS, Sawicki JA, Cotsarelis G. Capturing and profiling adult hair follicle stem cells. *Nat Biotechnol*. 2004; 22:411–417. [PubMed: 15024388]

- Nilsson M, Uden AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, Toftgard R. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. *Proc Natl Acad Sci U S A*. 2000; 97:3438–3443. [PubMed: 10725363]
- Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. *Science*. 1997; 276:817–821. [PubMed: 9115210]
- Wang C. *Cell Stem Cell*. 2011
- Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, Sotiropoulou PA, Blanpain C. Identification of the cell lineage at the origin of basal cell carcinoma. *Nat Cell Biol*. 2010; 12:299–305. [PubMed: 20154679]